A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)
A legfontosabb adatok
- Ki végzi
- Imugene Limited
- Hol
- Ausztrália és Tajvan7 helyszín, 2 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 7 fő vett részt
- Kezdés
- 2022. aug. 17.
- Befejezés
- 2024. ápr. 4.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- IMU-131
- Ramucirumab plus Paclitaxel
- Pembrolizumab
- A regiszteradat frissítve
- 2025. május 11.
- Miért állt le
- Study was discontinued because of slow enrollment and organizational priorities and not because of any findings related to safety or efficacy.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 years with confirmed diagnosis of advanced or metastatic HER2/neu overexpressing gastric or GEJ adenocarcinoma
- Progressed on or after trastuzumab therapy
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Life expectancy of a minimum of 3 months
- At least one measurable lesion as defined by RECIST 1.1 criteria and assessed by the local investigator
- HER2/neu overexpression assessed using post-progression fresh or archival tissue, or post-progression pathology report
- Adequate left ventricular ejection function at baseline, defined as left ventricular ejection fraction (LVEF) > 50% by echocardiogram or Multi Gated Acquisition (MUGA) scan
- Adequate hematologic, liver and renal function
- A female patient of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 120 days after the last dose of assigned treatment
Ki nem vehet részt
- Concurrent active malignancy except for adequately controlled limited basal cell carcinoma of the skin
- Systemic chemotherapy or major surgery within 28 days before starting study treatment and recovered from all adverse events ≤ Grade 1 or baseline with possible exceptions for neuropathy and endocrine-related AEs
- Received prior radiotherapy within 2 weeks of start of study treatment and recovered from all radiation-related toxicities and not require corticosteroids; or history of radiation pneumonitis
- Previous treatment with trastuzumab-deruxtecan or any other anti-HER2 therapy (except trastuzumab)
- Prior organ transplantation, including allogenic stem-cell transplantation
- Chronic immunosuppressive therapy within 7 days prior the first dose of study drug
- Current participation or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
- Any vaccination within 30 days prior to starting study treatment
- Arm 2 only: Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
- Arm 2 only: Has received prior therapy with an ICI or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from treatment due to a grade 3 or higher adverse event
- Previous malignant disease (other than primary malignancy) within the last 5 years, except basal or squamous cell carcinoma of the skin or cervical carcinoma in situ
- Clinically significant cardiovascular disease, or other diseases that in the Investigator's opinion may influence the patient's tolerance to study treatment
- Active, known, or suspected autoimmune disease
- History of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease
- Positivity for human immunodeficiency virus (HIV) (HIV 1/2 antibodies) or active hepatitis B (HBsAg reactive) or active hepatitis C (HCV ribonucleic acid [RNA] qualitative) infection
- Pleural effusion or ascites requiring more than weekly drainage
- Pregnant or lactating females
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a Phase 2, signal generating, open-label, 2-Arm, non-randomized study, in patients with metastatic HER2/neu over-expressing gastric cancer or gastroesophageal adenocarcinomas.
A vizsgálat 2 csoportja
- Arm 1: HER-Vaxx in combination with chemotherapy (ramucirumab plus paclitaxel)A vizsgált kezelés
Patients who have received an immune checkpoint inhibitor (ICI) previously will exclusively be enrolled in Arm 1 treated with HER-Vaxx (IM) in combination with chemotherapy (ramucirumab plus paclitaxel)
Kezelés: IMU-131 és Ramucirumab plus Paclitaxel
- Arm 2: HER-Vaxx in combination with pembrolizumabA vizsgált kezelés
Arm 2 will investigate the combination of HER-Vaxx plus pembrolizumab in patients who are naïve to ICI treatment including patients who have had chemotherapy only treatment after progression on trastuzumab. As the combination treatment has not been investigated, Arm 2 is planned to initiate with a safety run-in phase.
Kezelés: IMU-131 és Pembrolizumab
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- nextHERIZON: An Open-Label, Signal Generating, Phase 2 Study of HER-Vaxx in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric or Gastroesophageal Junction (GEJ) Adenocarcinomas Who Have Previously Received Trastuzumab and Progressed on This Treatment
- A regiszteradat frissítve
- 2025. május 11.